A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
Status:
Completed
Trial end date:
2019-03-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of this drug (MEDI-551)
in participants with advanced B-cell malignancies. Expansion to occur at maximum tolerated
dose (MTD), or if not reached, at optimal biologic dose (OBD).